Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felicia Cosman

Showing results (41-50 of 117) with videos related to

Pageof 12
Sort By:
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|July 5, 2023
Romosozumab Efficacy in Postmenopausal Women With No Prior Fracture Who Fulfill Criteria for Very High Fracture RiskMichael R McClung, Donald Betah, Cynthia Deignan, et al.
Bone|October 24, 2006
Effects of cyclic vs. daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activityAkiko Iida-Klein, Shi Shou Lu, Felicia Cosman, et al.
Current Medical Research and Opinion|March 16, 2007
A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosisDeborah T Gold, Bradley C Martin, Jennifer R Frytak, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 18, 2007
Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human iliumRobert Lindsay, Hua Zhou, Felicia Cosman, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|February 27, 2016
Effects of Daily or Cyclic Teriparatide on Bone Formation in the Iliac Crest in Women on No Prior Therapy and in Women on AlendronateDavid W Dempster, Felicia Cosman, Hua Zhou, et al.
Calcified Tissue International|February 8, 2012
Responses of urinary N-telopeptide and renal calcium handling to PTH infusion after treatment with estrogen, raloxifene, and tamoxifenCarolina A M Kulak, Merav Baz-Hecht, Jeri Nieves, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 5, 2005
Males have larger skeletal size and bone mass than females, despite comparable body sizeJeri W Nieves, Carmelo Formica, Jamie Ruffing, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 10, 2013
Goal-directed treatment of osteoporosisSteven R Cummings, Felicia Cosman, Richard Eastell, et al.
The Journal of Clinical Endocrinology and Metabolism|July 14, 2020
Cardiovascular Safety of Abaloparatide in Postmenopausal Women With Osteoporosis: Analysis From the ACTIVE Phase 3 TrialFelicia Cosman, Linda R Peterson, Dwight A Towler, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 23, 2024
Romosozumab followed by denosumab versus denosumab only: a post hoc analysis of FRAME and FRAME extensionFelicia Cosman, Mary Oates, Donald Betah, et al.
Pageof 12

Showing results (41-50 of 117) with videos related to

Sort By:
Pageof 12
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|July 5, 2023
Romosozumab Efficacy in Postmenopausal Women With No Prior Fracture Who Fulfill Criteria for Very High Fracture RiskMichael R McClung, Donald Betah, Cynthia Deignan, et al.
Bone|October 24, 2006
Effects of cyclic vs. daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activityAkiko Iida-Klein, Shi Shou Lu, Felicia Cosman, et al.
Current Medical Research and Opinion|March 16, 2007
A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosisDeborah T Gold, Bradley C Martin, Jennifer R Frytak, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 18, 2007
Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human iliumRobert Lindsay, Hua Zhou, Felicia Cosman, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|February 27, 2016
Effects of Daily or Cyclic Teriparatide on Bone Formation in the Iliac Crest in Women on No Prior Therapy and in Women on AlendronateDavid W Dempster, Felicia Cosman, Hua Zhou, et al.
Calcified Tissue International|February 8, 2012
Responses of urinary N-telopeptide and renal calcium handling to PTH infusion after treatment with estrogen, raloxifene, and tamoxifenCarolina A M Kulak, Merav Baz-Hecht, Jeri Nieves, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 5, 2005
Males have larger skeletal size and bone mass than females, despite comparable body sizeJeri W Nieves, Carmelo Formica, Jamie Ruffing, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 10, 2013
Goal-directed treatment of osteoporosisSteven R Cummings, Felicia Cosman, Richard Eastell, et al.
The Journal of Clinical Endocrinology and Metabolism|July 14, 2020
Cardiovascular Safety of Abaloparatide in Postmenopausal Women With Osteoporosis: Analysis From the ACTIVE Phase 3 TrialFelicia Cosman, Linda R Peterson, Dwight A Towler, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|July 23, 2024
Romosozumab followed by denosumab versus denosumab only: a post hoc analysis of FRAME and FRAME extensionFelicia Cosman, Mary Oates, Donald Betah, et al.
Pageof 12